Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00750139
Recruitment Status : Completed
First Posted : September 10, 2008
Results First Posted : January 29, 2013
Last Update Posted : April 26, 2013
Information provided by (Responsible Party):
Merz North America, Inc.

September 8, 2008
September 10, 2008
February 13, 2012
January 29, 2013
April 26, 2013
August 2008
August 2009   (Final data collection date for primary outcome measure)
Percentage of Subjects With Complete Cure at Week 6. [ Time Frame: Week 6 ]

The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.

The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.

Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.

NAFT-500 cream to placebo at the 2 week time point post treatment with complete cure defined as negative mycology results from the central laboratory and negative signs and symptoms. [ Time Frame: two weeks post treatment ]
Complete list of historical versions of study NCT00750139 on Archive Site
Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6 [ Time Frame: Week 6 ]
Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.
Treatment Effectiveness;Mycological Cure;Clinical Success;Clinical Cure;Physicians Global Evaluation;Subject Satisfaction Assessment [ Time Frame: two weeks post treatment ]
Not Provided
Not Provided
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
To evaluate the efficacy and safety of NAFT-500 compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea pedis.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Tinea Pedis
  • Athlete's Foot
  • Drug: NAFT-500
    topical cream 1 application every day up to 4 weeks weeks
  • Drug: Placebo 2-weeks
    placebo cream 1 application every day for up to 4 weeks
  • Drug: Naftin 1%
    topical allylamine cream applied once a day for up to 4 weeks
  • Drug: Placebo 4-weeks
    topical placebo cream applied once a day for up to 4 weeks
  • Experimental: 1
    Naftin 2% cream applied daily for 2 weeks
    Intervention: Drug: NAFT-500
  • Placebo Comparator: 2
    Placebo cream applied daily for two weeks
    Intervention: Drug: Placebo 2-weeks
  • Active Comparator: 3
    Active comparator applied daily for 4 weeks
    Intervention: Drug: Naftin 1%
  • Placebo Comparator: 4
    placebo cream applied daily for 4 weeks
    Intervention: Drug: Placebo 4-weeks
Parish LC, Parish JL, Routh HB, Fleischer AB Jr, Avakian EV, Plaum S, Hardas B. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011 Nov;10(11):1282-8.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Review and sign a statement of Informed Consent and HIPAA authorization.
  2. For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
  3. Males or non-pregnant females ≥12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.
  4. Presence of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus)based on signs and symptoms.
  5. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
  6. Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.
  7. Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion Criteria:

  1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
  2. Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
  3. Subjects with a known hypersensitivity to study medications or their components.
  4. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
  5. Uncontrolled diabetes mellitus.
  6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
  7. Current diagnosis of immunocompromising conditions.
  8. Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.
  9. Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis, or bacterial skin infection.
  10. Extremely severe tinea pedis (incapacitating).
  11. Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized or post menopausal for at least 2 years are not considered to be of childbearing potential).For the purposes of this study, acceptable forms of birth control include: oral contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of condom and spermicide), IUD, and abstinence with second acceptable method should subject become sexually active.
  12. Subjects using the following medications:

    • Topical anti-fungal therapy, foot/shoe powders, or topical corticosteroids applied to the feet within 14 days prior to randomization. Topical terbinafine, butenafine,and naftifine within 30 days prior to randomization
    • Oral anti-fungal therapies 3 months (8 months for oral terbinafine) prior to randomization
    • Systemic antibiotic or corticosteroid treatment within 30 days of randomization
    • Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
    • Investigational drug within 30 days of randomization
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
MUS 90200-0736/1
Not Provided
Not Provided
Merz North America, Inc.
Merz North America, Inc.
Not Provided
Principal Investigator: Lawrence Parish, MD Paddington Testing Company
Merz North America, Inc.
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP